glp-1 and osteoporosis AAOS | A new study presented at #AAOS2026 revealed use may be linked to a 29% higher risk of after five years. As use of GIP and GLP-2 together improve
Description
Martn ED, Snchez-Perez A, Trejo JL, et al

doi: 10.1093/ije/dyr233 21 MacKinnonDPFairchildAJFritzMS
Thus, the growth in GLP-1 RA prescribing among patients with PCOS may reflect a combination of general expansion in GLP-1 RA use and the high prevalence of metabolic indications in this population

doi: 10.1002/oby.22758, 97 McLeanB

Indeed, adverse GI effects such as nausea may be more frequently experienced by women as demonstrated by a study on cotadutide (dual agonist of the GLP-1 and glucagon receptors), which attributed this effect to slower drug absorption rates in women (79)
:max_bytes(150000):strip_icc()/Health-GettyImages-1688221666-08174a5c481b43a5b01c5a8f2d71f3eb.jpg)
doi: 10.1210/jc.82.3.786